2,105 results on '"Scuteri, A"'
Search Results
2. Glucose-6-phosphate dehydrogenase deficiency accelerates arterial aging in diabetes
- Author
-
Scuteri, Angelo, Morrell, Christopher H., AlGhatrif, Majd, Orru, Marco, Fiorillo, Edoardo, Marongiu, Michele, Schlessinger, David, Cucca, Francesco, and Lakatta, Edward G.
- Published
- 2024
- Full Text
- View/download PDF
3. Contributors
- Author
-
Agabiti-Rosei, Claudia, primary, Agabiti-Rosei, Enrico, additional, Agnoletti, Davide, additional, Alastruey, Jordi, additional, AlGhatrif, Majd, additional, Almada, Horacio, additional, Ángela, Sardella, additional, Argyris, Antonios, additional, Aristizabal, Dagnovar, additional, Armeni, Eleni, additional, Avolio, Alberto, additional, Badariene, Jolita, additional, Badhwar, Smriti, additional, Barbosa, Eduardo Costa Duarte, additional, Barroso, Weimar Kunz Sebba, additional, Bascetin, Rümeyza, additional, Baynard, Tracy, additional, Becerra, Carlos Ramos, additional, Bennett, Nadia, additional, Bianchini, Elisabetta, additional, Bohn, Lucimere, additional, Borghi, Claudio, additional, Bortolotto, Luiz Aparecido, additional, Boutouyrie, Pierre, additional, Bruno, Rosa Maria, additional, Burnier, Michel, additional, Butlin, Mark, additional, Calabria, Fabiana, additional, Camafort, Miguel, additional, Cavero-Redondo, Iván, additional, Challande, Pascal, additional, Chirinos, Julio A., additional, Climie, Rachel Emma, additional, Cockcroft, John, additional, Cotter, Jorge, additional, Cruickshank, J. Kennedy, additional, Cunha, Pedro Guimarães, additional, Damianaki, Aikaterini, additional, De Backer, Tine, additional, De Buyzere, Marc L., additional, De Caterina, Raffaele, additional, De Ciuceis, Carolina, additional, Debette, Stephanie, additional, Edsfeldt, Andreas, additional, Fernhall, Bo, additional, Ferreira, Isabel, additional, Fisher, Simon, additional, Forcada, Pedro, additional, S. Franklin, Stanley, additional, Garcia, Ricardo, additional, Georgiopoulos, Georgios, additional, Ghiadoni, Lorenzo, additional, Goncalves, Isabel, additional, Gottsäter, Mikael, additional, Graham, Delyth, additional, Greene, Katherine, additional, Guala, Andrea, additional, Hametner, Bernhard, additional, Hashimoto, Junichiro, additional, Hering, Dagmara, additional, Hibner, Brooks A., additional, Højlund, Kurt, additional, Hughes, Alun, additional, Ikonomidis, Ignatios, additional, Johansson, Madeleine, additional, Jordan, Jens, additional, Kario, Kazuomi, additional, Kotsis, Vasilios, additional, Kozakova, Michaela, additional, Lacolley, Patrick, additional, Lagrange, Jérémy, additional, Lakatta, Edward G., additional, Lambrinoudaki, Irene, additional, Laucyte-Cibulskiene, Agne, additional, Laurent, Stéphane, additional, Lopes, Wendell Arthur, additional, Lopez-Jaramillo, Patricio, additional, Magalhaes, Lucélia Batista Neves Cunha, additional, Magnussen, Costan G., additional, Mavraganis, Georgios, additional, Mayer, Christopher Clemens, additional, Maynard, Hannah, additional, McBride, Martin W., additional, McDonnell, Barry J., additional, McEniery, Carmel M., additional, Mota, Jorge, additional, Motl, Robert W., additional, Mozos, Ioana, additional, Muiesan, Maria Lorenza, additional, Muñoz, Ernesto Cardona, additional, Narkiewicz, Krzysztof, additional, Nemcsik, János, additional, Neves, Mario Fritsch, additional, Nilsson, Jan, additional, Nilsson, Peter M., additional, Oberhoffer-Fritz, Renate, additional, Ochoa, Juan Eugenio, additional, Okawa, Jaqueline Lyrio Bermudes, additional, Okawa, Rogério Toshiro Passos, additional, Olesen, Thomas Bastholm, additional, Oliveira, José, additional, Oliveras, Anna, additional, Hecht Olsen, Michael, additional, Ortiz, Luis Garcia, additional, Pahkala, Katja, additional, Paini, Anna, additional, Palombo, Carlo, additional, Parati, Gianfranco, additional, Park, Chloe, additional, Pavlidis, George, additional, Piani, Federica, additional, Pierce, Gary L., additional, Pizzala, Pablo G., additional, Protogerou, Athanase D., additional, Pucci, Giacomo, additional, Pupi, Luis María, additional, Pupi, Pablo María, additional, Raitakari, Olli T., additional, Rajkumar, C., additional, Ramirez, Agustín, additional, Raso, Francesco Mattace, additional, Recchia, Fabio Anastasio, additional, Regnault, Veronique, additional, Rietzschel, Ernst, additional, Rizzoni, Damiano, additional, Rodilla, Enrique, additional, Rovio, Suvi P., additional, Ryliskyte, Ligita, additional, Salvi, Paolo, additional, Sanchez, Ramiro, additional, Sáry, Javier Osvaldo, additional, Schillaci, Giuseppe, additional, Schmidt-Trucksäss, Arno, additional, Scuteri, Angelo, additional, Segers, Patrick, additional, Sharman, James, additional, Sierra, Cristina, additional, Stamatelopoulos, Kimon, additional, Steckelings, Ulrike M., additional, Stehouwer, Coen D.A., additional, Stoner, Lee, additional, Taddei, Stefano, additional, Terentes-Printzios, Dimitrios, additional, Tomiyama, Hirofumi, additional, Trivett, Cara, additional, Tsioufis, Costas, additional, Turroni, Silvia, additional, Urbina, Elaine M., additional, Van Bortel, L., additional, van de Laar, Roel J., additional, van der Heide, Frank C.T., additional, Vázquez, Susana, additional, Vishram-Nielsen, Julie, additional, Vlachopoulos, Charalambos, additional, Vlastos, Dimitrios, additional, Walker, Ashley, additional, Wang, Mingyi, additional, Weber, Thomas, additional, Xaplanteris, Panagiotis, additional, Zanoli, Luca, additional, and Zhou, Manshi, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial
- Author
-
Damiana Scuteri, Martina Pagliaro, Isabel Mantia, Marianna Contrada, Loris Pignolo, Paolo Tonin, Pierluigi Nicotera, Giacinto Bagetta, Maria Tiziana Corasaniti, and the Pilot BRAINAID Trial investigators
- Subjects
NanoBEO ,agitation ,dementia ,behavioural and psychological symptoms of dementia ,pain ,pilot clinical trial ,Therapeutics. Pharmacology ,RM1-950 - Abstract
BackgroundAn estimated 57.4 million people live with dementia worldwide, with the social burden of the disease steadily growing. Despite the approval of lecanemab and ongoing trials, there is still a lack of effective and safe treatments for behavioral and psychological symptoms of dementia (BPSD), which affect 99% of patients. Agitation is one of the most disabling BPSD, with a cross-sectional prevalence of ≥50% in nursing homes, and refers to help-seeking behavior in response to various sources of discomfort, among which pain is a crucial component.MethodsThis pilot phase of the BRAINAID (NCT04321889) trial aimed to assess the effectiveness of the patented nanotechnological device NanoBEO in older (≥65 years) people with severe dementia. This randomized placebo-controlled trial, with quadruple masking that involved all operators and participants, followed the SPIRIT and CONSORT statements. A total of 29 patients completed the trial. The patients were randomly allocated in a 1:1 ratio to the NanoBEO or placebo group, and the corresponding product was applied on both arms once daily for 4 weeks, with a 4-week follow-up period. The primary endpoint was efficacy against agitation. The secondary endpoints were efficacy against agitation at follow-up and efficacy against pain. Any adverse events were reported, and biochemical analyses were performed.ResultsThe NanoBEO intervention reduced the frequency (28%) and level of disruptiveness of agitated behaviors. The effect on frequency was statistically significant after 2 weeks of treatment. The efficacy of NanoBEO on agitated behaviors lasted for the entire 4-week treatment period. No additional psychotropic drugs were prescribed throughout the study duration. The results after 1 week of treatment demonstrated that NanoBEO had statistically significant analgesic efficacy (45.46% improvement in pain intensity). The treatment was well tolerated.DiscussionThis trial investigated the efficacy of NanoBEO therapy in managing agitation and pain in dementia. No need for rescue medications was recorded, strengthening the efficacy of NanoBEO in prolonged therapy for advanced-stage dementia and the usefulness of the intervention in the deprescription of potentially harmful drugs. This study provided a robust rationale for the application of NanoBEO in a subsequent large-scale pivotal trial to allow clinical translation of the product.Clinical Trial Registration:ClinicalTrials.gov, identifier NCT04321889.
- Published
- 2024
- Full Text
- View/download PDF
5. Effectiveness of a randomized intervention by a geriatric team in frail hospital inpatients in non‐geriatric settings: FRAILCLINIC project
- Author
-
Marta Checa‐López, Alba Costa‐Grille, Alejandro Álvarez‐Bustos, Jose A. Carnicero‐Carreño, Alan Sinclair, Angelo Scuteri, Francesco Landi, Juan José Solano‐Jaurrieta, Srikanth Bellary, and Leocadio Rodríguez‐Mañas
- Subjects
Frailty ,Hospitalization ,Intervention ,Functional decline ,Mortality ,Diseases of the musculoskeletal system ,RC925-935 ,Human anatomy ,QM1-695 - Abstract
Abstract Background Little research has been undertaken on the benefits of frailty management within different hospital settings. The objective of this study is to provide evidence on the viability and effectiveness of frailty management in non‐geriatric hospital settings on mortality and functional decline after discharge. Methods Data from the FRAILCLINIC (NCT02643069) study were used. FRAILCLINIC is a randomized controlled trial developed in non‐geriatric hospital inpatient settings (emergency room, cardiology and surgery) from Spain (2), Italy (2) and the United Kingdom (1). Inpatients must met frailty criteria (according to the Frailty Phenotype and/or FRAIL scale), ≥75 years old. The control group (CG) received usual care. The intervention group (IG) received comprehensive geriatric assessment (CGA) and a coordinated intervention consisting in recommendations to the treating physician about polypharmacy, delirium, falls, nutrition and physical exercise plus a discharge plan. The main outcomes included functional decline (worsening ≥5 points in Barthel Index) and mortality at 3 months. We used multivariate logistic regression models adjusted by age, gender and the Charlson index. Intention‐to‐treat (ITT) and per‐protocol (PP) analyses were used. Results Eight hundred twenty one participants (IG: 416; mean age 83.00 ± 4.91; 51.44% women; CG: 405; mean age 82.46 ± 6.03; 52.35% women) were included. In the IG, 77.16% of the participants followed the geriatric team's recommendations as implemented by the treating physicians. The intervention showed a benefit on functional decline and mortality [OR: 0.67(0.47–0.96), P‐value 0.027 and 0.29(0.14–0.57), P‐value
- Published
- 2024
- Full Text
- View/download PDF
6. Bacteremia from streptococcus constellatus revealing a gastrointestinal stromal tumor
- Author
-
Salvatore Chessa, Elena Belfiori, Giulia Mandis, Enrico Urru, Giovanna Manconi, and Angelo Scuteri
- Subjects
Streptococcus constellatus ,Bacteriemia ,Pyogenic liver abscesses ,GIST ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Pyogenic Liver Abscesses (PLA) are the most common type of visceral abscess. They generally develop in a context of biliary disease or hematogenous seeding, but a complete diagnostic work-up is always required in order not to miss other important causes, including above all malignancies of the gastro-intestinal tract. Case presentation Herein, we report a particular case of a 80 years-old immunocompetent woman hospitalized for sepsis. At the end of the diagnostic process, Streptococcus constellatus (Sc) was identified as the cause of sepsis, multiple PLA were found together with a previous unknown ileal malignancy. We speculated about a possible correlation among these three entities (i.e. sepsis from Sc, PLA and tumors). Conclusions Detection of Sc in blood should raise red flags in clinicians as aggressive clinical presentation are possible.
- Published
- 2024
- Full Text
- View/download PDF
7. Thermal and Visual Tracking of Photovoltaic Plants for Autonomous UAV inspection
- Author
-
Morando, Luca, Recchiuto, Carmine Tommaso, Callà, Jacopo, Scuteri, Paolo, and Sgorbissa, Antonio
- Subjects
Computer Science - Robotics - Abstract
Since photovoltaic (PV) plants require periodic maintenance, using Unmanned Aerial Vehicles (UAV) for inspections can help reduce costs. The thermal and visual inspection of PV installations is currently based on UAV photogrammetry. A UAV equipped with a Global Positioning System (GPS) receiver is assigned a flight zone: the UAV will cover it back and forth to collect images to be later composed in an orthomosaic. The UAV typically flies at a height above the ground that is appropriate to ensure that images overlap even in the presence of GPS positioning errors. However, this approach has two limitations. Firstly, it requires to cover the whole flight zone, including "empty" areas between PV module rows. Secondly, flying high above the ground limits the resolution of the images to be later inspected. The article proposes a novel approach using an autonomous UAV equipped with an RGB and a thermal camera for PV module tracking. The UAV moves along PV module rows at a lower height than usual and inspects them back and forth in a boustrophedon way by ignoring "empty" areas with no PV modules. Experimental tests performed in simulation and an actual PV plant are reported., Comment: 17 pages, 34 figures
- Published
- 2022
8. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
- Author
-
Damiana Scuteri, Giulio Pocobelli, Yoichi Sakurada, Rossella Russo, Paolo Tonin, Pierluigi Nicotera, Giacinto Bagetta, Maria Tiziana Corasaniti, and Carlo Nucci
- Subjects
Primary open-angle glaucoma (POAG) ,Genetic variants ,PRISMA 2020 ,Pharmacological therapy ,Efficacy ,Safety ,Biology (General) ,QH301-705.5 - Abstract
Abstract The social impact of glaucoma is worth of note: primary open-angle glaucoma (POAG) is one of the leading causes of irreversible blindness worldwide, affecting some 68.56 million people with overall prevalence of 2.4%. Since one of the main risk factors for the development of POAG is the increase of intraocular pressure (IOP) causing retinal ganglion cells death, the medical treatment of POAG consists in the use of drugs endowed with neuroprotective effect and able to reduce IOP. These drugs include beta-blockers, prostaglandin analogues, carbonic anhydrase inhibitors, alpha or cholinergic agonists and rho kinase inhibitors. However, not all the patients respond to the same extent to the therapy in terms of efficacy and safety. Genetics and genome wide association studies have highlighted the occurrence of mutations and polymorphisms influencing the predisposition to develop POAG and its phenotype, as well as affecting the response to pharmacological treatment. The present systematic review and meta-analysis aims at identifying genetic variants and at verifying whether these can influence the responsiveness of patients to therapy for efficacy and safety. It follows the most updated Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 recommendations. The literature search was conducted consulting the most relevant scientific databases, i.e. PubMed/MEDLINE, Scopus, Web of Science and Public Health Genomics and Precision Health Knowledge Base up to June 14th, 2023. The search retrieved 1026 total records, among which eight met the eligibility criteria for inclusion in the analysis. The results demonstrated that the most investigated pharmacogenetic associations concern latanoprost and timolol, and that efficacy was studied more in depth than safety. Moreover, the heterogeneity of design and paucity of studies prompt further investigation in randomized clinical trials. In fact, adequately powered and designed pharmacogenetic association studies are needed to provide body of evidence with good certainty for a more appropriate use of medical therapy in POAG. PROSPERO registration: CRD42023434867.
- Published
- 2023
- Full Text
- View/download PDF
9. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
- Author
-
Scuteri, Damiana, Pocobelli, Giulio, Sakurada, Yoichi, Russo, Rossella, Tonin, Paolo, Nicotera, Pierluigi, Bagetta, Giacinto, Corasaniti, Maria Tiziana, and Nucci, Carlo
- Published
- 2023
- Full Text
- View/download PDF
10. Epigenetic and nanotechnology alliance to fight stroke-induced brain damage
- Author
-
Giacinto Bagetta, Maria Tiziana Corasaniti, and Damiana Scuteri
- Subjects
stroke ,NCX1 ,miRNA 103/107 ,lipid nanoparticles ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2024
- Full Text
- View/download PDF
11. Genetic and biomarker modulation of arterial stiffness change in the SardiNIA population cohort
- Author
-
Nigus G. Asefa, Osorio Meirelles, Edward Lakatta, Edoardo Fiorillo, Angelo Scuteri, Francesco Cucca, Michele Marongiu, Alessandro Delitala, David Schlessinger, and Lenore J. Launer
- Subjects
arterial stiffness ,longitudinal ,pulse wave velocity ,genetic variant ,lipid ,inflammation ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background and aimsArterial stiffness (AS), quantified by pulse wave velocity (PWV), arises due to impaired arterial elastic tissue and smooth muscle dysfunction. We aimed to examine the longitudinal association of genetic, lipid and inflammation biomarkers with PWV and how these associations may change with aging.Materials and methodsWe utilized genotype and four time-point biomarker data from the SardiNIA cohort [n = 6,301; mean baseline age 43.3 (SD 17.3); 58% females]. To investigate the association of PWV with genetic variants, lipid, and inflammation biomarkers, we employed linear mixed modeling, using age as the time scale. Biomarkers exhibiting significant longitudinal associations were categorized into tertiles and individuals within the second tertile or those with heterozygous alleles were excluded, leaving a cohort of 2,000 individuals. This cohort was further divided into four risk groups: low genetic and low biomarker (L-L), low genetic and high biomarker (L-H), high genetic and low biomarker (H-L), and high genetic and high biomarker risk (H-H). Subsequent analyses focused on these risk groups to assess their association to PWV with time.ResultsUsing the complete dataset, we found a significant longitudinal association of total cholesterol (TC), triglycerides (TG), fibrinogen (FGN), and total white blood cell count (TWBC) with PWV, all with p
- Published
- 2024
- Full Text
- View/download PDF
12. Dilated hypertrophic phenotype of the carotid artery is associated with accelerated age-associated central arterial stiffening
- Author
-
AlGhatrif, Majd, Lakatta, Edward G., Morrell, Christopher H., Fegatelli, Danilo Alunni, Fiorillo, Edoardo, Marongiu, Michele, Schlessinger, David, Cucca, Francesco, and Scuteri, Angelo
- Published
- 2023
- Full Text
- View/download PDF
13. Basic, Translational, and Clinical Research on Dementia
- Author
-
Giacinto Bagetta, Daniele Bano, and Damiana Scuteri
- Subjects
n/a ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The global impact of dementia is an increasing area of concern and, according to the Alzheimer’s Disease International (ADI) World Alzheimer Report 2021, up to 90% of dementia patients in low- and middle-income countries are not diagnosed [...]
- Published
- 2024
- Full Text
- View/download PDF
14. Role of Spinal Cholecystokinin Octapeptide, Nociceptin/Orphanin FQ, and Hemokinin-1 in Diabetic Allodynia
- Author
-
Takafumi Hayashi, Syu-ichi Kanno, Chizuko Watanabe, Damiana Scuteri, Yasuyuki Agatsuma, Akiyoshi Hara, Giacinto Bagetta, Tsukasa Sakurada, and Shinobu Sakurada
- Subjects
cholecystokinin octapeptide ,nociceptin/orphanin FQ ,hemokinin-1 ,diabetic allodynia ,spinal cord ,Biology (General) ,QH301-705.5 - Abstract
A complication of diabetes is neuropathic pain, which is difficult to control with medication. We have confirmed that neuropathic pain due to mechanical allodynia in diabetic mice is mediated by a characteristic neuropeptide in the spinal cord. We evaluated the strength of mechanical allodynia in mice using von Frey filaments. When mice were intravenously injected with streptozotocin, mechanical allodynia appeared 3 days later. Antibodies of representative neuropeptides were intrathecally (i.t.) administered to allodynia-induced mice 7 days after the intravenous administration of streptozotocin, and allodynia was reduced by anti-cholecystokinin octapeptide antibodies, anti-nociceptin/orphanin FQ antibodies, and anti-hemokinin-1 antibodies. In contrast, i.t.-administered anti-substance P antibodies, anti-somatostatin antibodies, and anti-angiotensin II antibodies did not affect streptozotocin-induced diabetic allodynia mice. Mechanical allodynia was attenuated by the i.t. administration of CCK-B receptor antagonists and ORL-1 receptor antagonists. The mRNA level of CCK-B receptors in streptozotocin-induced diabetic allodynia mice increased in the spinal cord, but not in the dorsal root ganglion. These results indicate that diabetic allodynia is caused by cholecystokinin octapeptide, nociceptin/orphanin FQ, and hemokinin-1 released from primary afferent neurons in the spinal cord that transmit pain to the brain via the spinal dorsal horn.
- Published
- 2024
- Full Text
- View/download PDF
15. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
- Author
-
M. T. Corasaniti, G. W. Lawrence, G. Bagetta, R. Iannacchero, A. Tarsitano, A. Monteleone, M. Pagliaro, P. Tonin, G. Sandrini, P. Nicotera, and D. Scuteri
- Subjects
onabotulinumtoxin A ,chronic migraine ,anti-CGRP monoclonal antibodies ,anti-CGRP-R monoclonal antibodies ,erenumab ,eptinezumab ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Chronic migraine is a disabling neurovascular disorder that ranks amongst the top causes of years lived with disability worldwide. The duration and the frequency of migraine affect cognitive and affective domains, inducing worsening of memory, executive functions, orientation and causing anxiety. Population-based studies report a worrying level of resistance to treatments. Therefore, this study aims: 1) to assess efficacy of monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) or its receptor (CGRP-R) for chronic migraine resistant to current preventatives; 2) to design a clinical trial protocol to evaluate the efficacy and safety of combination therapy utilizing anti-CGRP/CGRP-R together with onabotulinumtoxin A in patients suffering from resistant chronic migraine; 3) to provide a molecular rationale for combination therapy. A controlled trial is warranted as pooled analysis of real-world data from our group highlighted that combined treatment provides ≥50% reduction vs. baseline (onabotulinumtoxin A) of monthly headache days (MHDs) in up to 58.8% of patients, but there has been only sparse application of this combined therapy to date. The mAbs chosen are: erenumab, because its combination effect with onabotulinumtoxin A improved symptoms in 65% of patients; eptinezumab, due to its faster action. The results highlight that early diagnosis of migraine improves therapeutic outcomes with mAbs alone, confirming their effectiveness and the need for an adequately powered clinical trial evaluating the safety and potential superior effectiveness of eptinezumab/erenumab and onabotulinumtoxin A together.
- Published
- 2023
- Full Text
- View/download PDF
16. Subclinical HMOD in Hypertension: Brain Imaging and Cognitive Function
- Author
-
Scuteri, Angelo and Antonelli Incalzi, Raffaele
- Published
- 2022
- Full Text
- View/download PDF
17. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review
- Author
-
Maria Tiziana Corasaniti, Giacinto Bagetta, Pierluigi Nicotera, Sabatino Maione, Paolo Tonin, Francesca Guida, and Damiana Scuteri
- Subjects
dementia ,autophagy ,autophagy inducers ,metformin ,resveratrol ,masitinib ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The social burden of dementia is remarkable since it affects some 57.4 million people all over the world. Impairment of autophagy in age-related diseases, such as dementia, deserves deep investigation for the detection of novel disease-modifying approaches. Several drugs belonging to different classes were suggested to be effective in managing Alzheimer’s disease (AD) by means of autophagy induction. Useful autophagy inducers in AD should be endowed with a direct, measurable effect on autophagy, have a safe tolerability profile, and have the capability to cross the blood–brain barrier, at least with poor penetration. According to the PRISMA 2020 recommendations, we propose here a systematic review to appraise the measurable effectiveness of autophagy inducers in the improvement of cognitive decline and neuropsychiatric symptoms in clinical trials and retrospective studies. The systematic search retrieved 3067 records, 10 of which met the eligibility criteria. The outcomes most influenced by the treatment were cognition and executive functioning, pointing at a role for metformin, resveratrol, masitinib and TPI-287, with an overall tolerable safety profile. Differences in sample power, intervention, patients enrolled, assessment, and measure of outcomes prevents generalization of results. Moreover, the domain of behavioral symptoms was found to be less investigated, thus prompting new prospective studies with homogeneous design. PROSPERO registration: CRD42023393456.
- Published
- 2024
- Full Text
- View/download PDF
18. Clusters of risk factors in metabolic syndrome and their influence on central blood pressure in a global study
- Author
-
Agne Laucyte-Cibulskiene, Chen-Huan Chen, John Cockroft, Pedro G. Cunha, Maryam Kavousi, Aleksandras Laucevicius, Maria Lorenza Muiesan, Ernst R. Rietzschel, Ligita Ryliskyte, Irina D. Strazhesko, Charalambos Vlachopoulos, Jorge Cotter, Ekatherina N. Dudinskaya, Nichola Gale, Fariba Ahmadizar, Francesco U. S. Mattace-Raso, Maggie Munnery, Pedro Oliveira, Anna Paini, Massimo Salvetti, Olga N. Tkacheva, Edward G. Lakatta, Peter M. Nilsson, and Angelo Scuteri
- Subjects
Medicine ,Science - Abstract
Abstract The effect of metabolic syndrome (MetS) and clusters of its components on central blood pressure (CBP) has not been well characterized. We aimed to describe the effect of MetS and clusters of its components on CBP in a large population and to identify whether this effect differs in men and women. We studied 15,609 volunteers (43% women) from 10 cohorts worldwide who participated in the Metabolic syndrome and Artery REsearch Consortium. MetS was defined according to the NCEP-ATP III criteria (GHTBW, glucose, high-density lipoprotein cholesterol, triglyceride, blood pressure, waist circumference). CBP was measured noninvasively and acquired from pulse wave analysis by applanation tonometry. MetS was associated with a 50% greater odds of having higher CSBP. After controlling for age, male sex, non HDL cholesterol, diabetes mellitus, and mean arterial pressure, only specific clusters of MetS components were associated with a higher CSBP; and some of them were significant in women but not in men. We identified “risky clusters” of MetS variables associated with high CSBP. Future studies are needed to confirm they identify subjects at high risk of accelerated arterial aging and, thus, need more intensive clinical management.
- Published
- 2022
- Full Text
- View/download PDF
19. Hericenone C attenuates the second phase of formalin-induced nociceptive behavior by suppressing the accumulation of CD11c-positive cells in the paw epidermis via phosphorylated P65
- Author
-
Li, Junhao, primary, Hamamura, Kengo, additional, Yoshida, Yuya, additional, Kawano, Shimpei, additional, Uchinomiya, Shohei, additional, Xie, Jiahongyi, additional, Scuteri, Damiana, additional, Fukuoka, Kohei, additional, Zaitsu, Orion, additional, Tsurusaki, Fumiaki, additional, Terada, Yuma, additional, Tsukamoto, Ryotaro, additional, Nishi, Takumi, additional, Fukuda, Taiki, additional, Oyama, Kosuke, additional, Bagetta, Giacinto, additional, Ojida, Akio, additional, Shimizu, Kuniyoshi, additional, Ohdo, Shigehiro, additional, and Matsunaga, Naoya, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Motor behavior induced by bergamot essential oil in experimental tasks is differentially modulated by pretreatment with metabotropic glutamate receptor 2/3 or 5 antagonists
- Author
-
Rombolà, Laura, primary, De Rasis, Enrica, additional, Sakurada, Shinobu, additional, Sakurada, Tsukasa, additional, Corasaniti, Maria Tiziana, additional, Bagetta, Giacinto, additional, Scuteri, Damiana, additional, and Morrone, Luigi Antonio, additional
- Published
- 2024
- Full Text
- View/download PDF
21. WCN24-1996 SPECIALIZATION IN NEPHROLOGY: TRAINING PROGRAMS AND TRENDS IN ARGENTINA
- Author
-
Marini, Alicia, primary, Sindín, Javier Robaina, additional, Najun, Carlos, additional, Scuteri, Rosa, additional, Andrade, Liliana, additional, and Di Bernardo, Juan José, additional
- Published
- 2024
- Full Text
- View/download PDF
22. The Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge: The Role of Drug Reconciliation
- Author
-
Cristina Vocca, Antonio Siniscalchi, Vincenzo Rania, Cecilia Galati, Gianmarco Marcianò, Caterina Palleria, Luca Catarisano, Ilaria Gareri, Marco Leuzzi, Lucia Muraca, Rita Citraro, Giacinto Nanci, Antonio Scuteri, Rosa Candida Bianco, Iolanda Fera, Antonietta Greco, Giacomo Leuzzi, Giovambattista De Sarro, Bruno D’Agostino, and Luca Gallelli
- Subjects
reconciliation ,deprescription ,older adult ,polytherapy ,Geriatrics ,RC952-954.6 - Abstract
Introduction: Drug–drug interactions (DDIs) represent an important clinical problem, particularly in older patients, due to polytherapy, comorbidity, and physiological changes in pharmacodynamic and pharmacokinetic pathways. In this study, we investigated the association between drugs prescribed after discharge from the hospital or clinic and the risk of DDIs with drugs used daily by each patient. Methods: We performed an observational, retrospective, multicenter study on the medical records of outpatients referred to general practitioners. DDIs were measured using the drug interaction probability scale. Potential drug interactions were evaluated by clinical pharmacologists (physicians) and neurologists. Collected data were analyzed using the Statistical Package for the Social Sciences. Results: During the study, we evaluated 1772 medical records. We recorded the development of DDIs in 10.3% of patients; 11.6% of these patients required hospitalization. Logistic regression showed an association among DDIs, sex, and the number of drugs used (p = 0.023). Conclusions: This observational real-life study shows that the risk of DDIs is common in older patients. Physicians must pay more attention after hospital discharge, evaluating the treatment to reduce the risk of DDIs.
- Published
- 2023
- Full Text
- View/download PDF
23. 2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play
- Author
-
Infantino, R., Boccella, S., Scuteri, D., Perrone, M., Ricciardi, F., Vitale, R.M., Bonsale, R., Parente, A., Allocca, I., Virtuoso, A., De Luca, C., Belardo, C., Amodeo, P., Gentile, V., Cirillo, G., Bagetta, G., Luongo, L., Maione, S., and Guida, F.
- Published
- 2022
- Full Text
- View/download PDF
24. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol
- Author
-
Scuteri, D., Guida, F., Boccella, S., Luongo, L., Maione, S., Tonin, P., Nicotera, P., Bagetta, G., and Corasaniti, M.T.
- Published
- 2022
- Full Text
- View/download PDF
25. Homo-AMPA in the periaqueductal grey modulates pain and rostral ventromedial medulla activity in diabetic neuropathic mice
- Author
-
Palazzo, Enza, Boccella, Serena, Marabese, Ida, Perrone, Michela, Belardo, Carmela, Iannotta, Monica, Scuteri, Damiana, De Dominicis, Emanuela, Pagano, Martina, Infantino, Rosmara, Bagetta, Giacinto, and Maione, Sabatino
- Published
- 2022
- Full Text
- View/download PDF
26. Editorial: Plant secondary metabolites: Potential therapeutic implications in neuropsychiatric disorders
- Author
-
Juan Francisco Rodríguez-Landa, Damiana Scuteri, and Lucía Martínez-Mota
- Subjects
aromatherapy ,antidepressant ,anxiolytic ,medicinal plant ,behavioral pharmacology ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Published
- 2023
- Full Text
- View/download PDF
27. PEA-OXA ameliorates allodynia, neuropsychiatric and adipose tissue remodeling induced by social isolation
- Author
-
Belardo, Carmela, Alessio, Nicola, Pagano, Martina, De Dominicis, Emanuela, Infantino, Rosmara, Perrone, Michela, Iannotta, Monica, Galderisi, Umberto, Rinaldi, Barbara, Scuteri, Damiana, Bagetta, Giacinto, Palazzo, Enza, Maione, Sabatino, and Luongo, Livio
- Published
- 2022
- Full Text
- View/download PDF
28. Role of imaging in rare COVID-19 vaccine multiorgan complications
- Author
-
Cau, Riccardo, Mantini, Cesare, Monti, Lorenzo, Mannelli, Lorenzo, Di Dedda, Emanuele, Mahammedi, Abdelkader, Nicola, Refky, Roubil, John, Suri, Jasjit S., Cerrone, Giulia, Fanni, Daniela, Faa, Gavino, Carriero, Alessandro, Scuteri, Angelo, Francone, Marco, and Saba, Luca
- Published
- 2022
- Full Text
- View/download PDF
29. Clusters of risk factors in metabolic syndrome and their influence on central blood pressure in a global study
- Author
-
Laucyte-Cibulskiene, Agne, Chen, Chen-Huan, Cockroft, John, Cunha, Pedro G., Kavousi, Maryam, Laucevicius, Aleksandras, Muiesan, Maria Lorenza, Rietzschel, Ernst R., Ryliskyte, Ligita, Strazhesko, Irina D., Vlachopoulos, Charalambos, Cotter, Jorge, Dudinskaya, Ekatherina N., Gale, Nichola, Ahmadizar, Fariba, Mattace-Raso, Francesco U. S., Munnery, Maggie, Oliveira, Pedro, Paini, Anna, Salvetti, Massimo, Tkacheva, Olga N., Lakatta, Edward G., Nilsson, Peter M., and Scuteri, Angelo
- Published
- 2022
- Full Text
- View/download PDF
30. Role of imaging in rare COVID-19 vaccine multiorgan complications
- Author
-
Riccardo Cau, Cesare Mantini, Lorenzo Monti, Lorenzo Mannelli, Emanuele Di Dedda, Abdelkader Mahammedi, Refky Nicola, John Roubil, Jasjit S. Suri, Giulia Cerrone, Daniela Fanni, Gavino Faa, Alessandro Carriero, Angelo Scuteri, Marco Francone, and Luca Saba
- Subjects
Covid-19 ,Vaccination ,Adverse events ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract As of September 18th, 2021, global casualties due to COVID-19 infections approach 200 million, several COVID-19 vaccines have been authorized to prevent COVID-19 infection and help mitigate the spread of the virus. Despite the vast majority having safely received vaccination against SARS-COV-2, the rare complications following COVID-19 vaccination have often been life-threatening or fatal. The mechanisms underlying (multi) organ complications are associated with COVID-19, either through direct viral damage or from host immune response (i.e., cytokine storm). The purpose of this manuscript is to review the role of imaging in identifying and elucidating multiorgan complications following SARS-COV-2 vaccination—making clear that, in any case, they represent a minute fraction of those in the general population who have been vaccinated. The authors are both staunch supporters of COVID-19 vaccination and vaccinated themselves as well.
- Published
- 2022
- Full Text
- View/download PDF
31. Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial.
- Author
-
Scuteri, Damiana, Pagliaro, Martina, Mantia, Isabel, Contrada, Marianna, Pignolo, Loris, Tonin, Paolo, Nicotera, Pierluigi, Bagetta, Giacinto, and Corasaniti, Maria Tiziana
- Subjects
PSYCHOTHERAPY ,HELP-seeking behavior ,PAIN management ,PSYCHIATRIC drugs ,DEMENTIA - Abstract
Background: An estimated 57.4 million people live with dementia worldwide, with the social burden of the disease steadily growing. Despite the approval of lecanemab and ongoing trials, there is still a lack of effective and safe treatments for behavioral and psychological symptoms of dementia (BPSD), which affect 99% of patients. Agitation is one of the most disabling BPSD, with a crosssectional prevalence of =50% in nursing homes, and refers to help-seeking behavior in response to various sources of discomfort, among which pain is a crucial component. Methods: This pilot phase of the BRAINAID (NCT04321889) trial aimed to assess the effectiveness of the patented nanotechnological device NanoBEO in older (=65 years) people with severe dementia. This randomized placebo-controlled trial, with quadruple masking that involved all operators and participants, followed the SPIRIT and CONSORT statements. A total of 29 patients completed the trial. The patients were randomly allocated in a 1:1 ratio to the NanoBEO or placebo group, and the corresponding product was applied on both arms once daily for 4 weeks, with a 4-week follow-up period. The primary endpoint was efficacy against agitation. The secondary endpoints were efficacy against agitation at follow-up and efficacy against pain. Any adverse events were reported, and biochemical analyses were performed. Results: The NanoBEO intervention reduced the frequency (28%) and level of disruptiveness of agitated behaviors. The effect on frequency was statistically significant after 2 weeks of treatment. The efficacy of NanoBEO on agitated behaviors lasted for the entire 4-week treatment period. No additional psychotropic drugs were prescribed throughout the study duration. The results after 1 week of treatment demonstrated that NanoBEO had statistically significant analgesic efficacy (45.46% improvement in pain intensity). The treatment was well tolerated. Discussion: This trial investigated the efficacy of NanoBEO therapy in managing agitation and pain in dementia. No need for rescue medications was recorded, strengthening the efficacy of NanoBEO in prolonged therapy for advanced-stage dementia and the usefulness of the intervention in the deprescription of potentially harmful drugs. This study provided a robust rationale for the application of NanoBEO in a subsequent large-scale pivotal trial to allow clinical translation of the product. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Scopolamine-Induced Memory Impairment in Mice: Effects of PEA-OXA on Memory Retrieval and Hippocampal LTP
- Author
-
Carmela Belardo, Serena Boccella, Michela Perrone, Antimo Fusco, Andrea Maria Morace, Federica Ricciardi, Roozbe Bonsale, Ines ELBini-Dhouib, Francesca Guida, Livio Luongo, Giacinto Bagetta, Damiana Scuteri, and Sabatino Maione
- Subjects
transient global amnesia ,cognition ,electrophysiology ,PEA-OXA ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Transient global amnesia, both persistent and transient, is a very common neuropsychiatric syndrome. Among animal models for amnesia and testing new drugs, the scopolamine test is the most widely used for transient global amnesia (TGA). This study examined the scopolamine-induced deficits in working memory, discriminative memory, anxiety, and motor activity in the presence of intranasal PEA-OXA, a dual antagonist of presynaptic α2 and H3 receptors. Male C57BL/6 mice were treated with intraperitoneal scopolamine (1 mg/kg) with or without pre-treatment (15 min) or post-treatment (15 min) with intranasal PEA-OXA (10 mg/kg). It was seen that scopolamine induced deficits of discriminative and spatial memory and motor deficit. These changes were associated with a loss of synaptic plasticity in the hippocampal dentate gyrus: impaired LTP after lateral entorhinal cortex/perforant pathway tetanization. Furthermore, hippocampal Ach levels were increased while ChA-T expression was reduced following scopolamine administration. PEA-OXA either prevented or restored the scopolamine-induced cognitive deficits (discriminative and spatial memory). However, the same treatment did not affect the altered motor activity or anxiety-like behavior induced by scopolamine. Consistently, electrophysiological analysis showed LTP recovery in the DG of the hippocampus, while the Ach level and ChoA-T were normalized. This study confirms the neuroprotective and pro-cognitive activity of PEA-OXA (probably through an increase in the extracellular levels of biogenic amines) in improving transient memory disorders for which the available pharmacological tools are obsolete or inadequate and not directed on specific pathophysiological targets.
- Published
- 2023
- Full Text
- View/download PDF
33. 2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play
- Author
-
R. Infantino, S. Boccella, D. Scuteri, M. Perrone, F. Ricciardi, R.M. Vitale, R. Bonsale, A. Parente, I. Allocca, A. Virtuoso, C. De Luca, C. Belardo, P. Amodeo, V. Gentile, G. Cirillo, G. Bagetta, L. Luongo, S. Maione, and F. Guida
- Subjects
Amyloid β (1−42) ,α2 adrenergic receptor ,Alzheimer Disease ,2-pentadecyl-2-oxazoline ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The 2-pentadecyl-2-oxazoline (PEA-OXA) is a natural compound with protective action in neuro-inflammation. We have previously shown that PEA-OXA behaves as an α2 adrenergic receptor (α2AR) antagonist and a putative protean agonist on histamine H3 receptors. Recently, neuroinflammation and monoaminergic neurotransmission dysfunction has drawn particular attention in Alzheimer Disease (AD) pathophysiology. In this context, the objective of this study was to investigate the effects of the dual-acting PEA-OXA in an AD-like model in mice. A combined computational and experimental approach was used to evaluate the ability of PEA-OXA to bind α2A-AR subtype, and to investigate the effects of PEA-OXA treatment on neuropathological (behavioural and functional) effects induced by soluble Amyloid β 1–42 (sAβ1–42) intracerebroventricular injection. Computational analysis revealed the PEA-OXA ability to bind the α2A-AR, a pharmacological target for AD, in two alternative poses, one overlapping the Na+ binding site. In vivo studies indicated that chronic treatment with PEA-OXA (10 mg/kg, os) restored the cognitive (discriminative and spatial memory) deficits and social impairments induced by sAβ injection. Consistently, electrophysiological analysis showed a recovery of the long-term potentiation in the hippocampus (Lateral Entorhinal Cortex-Dentate Gyrus pathway), while neuroinflammation, i.e., increased pro-inflammatory cytokines levels and microglia cells density were reduced. These data provide the basis for further investigation of the pro-cognitive aptitude of PEA-OXA by proposing it as an adjuvant in the treatment in AD, for which the available pharmacological approaches remain unsatisfactory. Moreover, this study offers new future direction in research investigating the role of α2AR in neuropsychiatric illness and therapies.
- Published
- 2022
- Full Text
- View/download PDF
34. New trends in pharmacological control of neuropsychiatric symptoms of dementia
- Author
-
Scuteri, Damiana, Corasaniti, Maria Tiziana, Tonin, Paolo, Nicotera, Pierluigi, and Bagetta, Giacinto
- Published
- 2021
- Full Text
- View/download PDF
35. Epigenetic and nanotechnology alliance to fight stroke-induced brain damage
- Author
-
Bagetta, Giacinto, primary, Corasaniti, Maria Tiziana, additional, and Scuteri, Damiana, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review
- Author
-
Corasaniti, Maria Tiziana, primary, Bagetta, Giacinto, additional, Nicotera, Pierluigi, additional, Maione, Sabatino, additional, Tonin, Paolo, additional, Guida, Francesca, additional, and Scuteri, Damiana, additional
- Published
- 2024
- Full Text
- View/download PDF
37. Genetic and biomarker modulation of arterial stiffness change in the SardiNIA population cohort
- Author
-
Asefa, Nigus G., primary, Meirelles, Osorio, additional, Lakatta, Edward, additional, Fiorillo, Edoardo, additional, Scuteri, Angelo, additional, Cucca, Francesco, additional, Marongiu, Michele, additional, Delitala, Alessandro, additional, Schlessinger, David, additional, and Launer, Lenore J., additional
- Published
- 2024
- Full Text
- View/download PDF
38. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
- Author
-
Damiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, Pierluigi Nicotera, and Giacinto Bagetta
- Subjects
polymorphisms ,SNPs ,methylation ,epigenetic ,migraine ,CGRP ,Medicine - Abstract
Abstract Background the interest of clinical reaseach in polymorphisms and epigenetics in migraine has been growing over the years. Due to the new era of preventative migraine treatment opened by monoclonal antibodies (mAbs) targeting the signaling of the calcitonin-gene related peptide (CGRP), the present systematic review aims at identifying genetic variants occurring along the CGRP pathway and at verifying whether these can affect the clinical features and the course of disease and the responsiveness of patients to therapy. Methods the literature search has been conducted consulting the most relevant scientific databases, i.e. PubMed/MEDLINE, Scopus, Web of Science, the Human Genome Epidemiology (HuGE) Published Literature database (Public Health Genomics Knowledge Base) and Clinicaltrials.gov from database inception until April 1, 2021. The process of identification and selection of the studies included in the analysis has followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) criteria for systematic reviews and meta-analyses and the guidance from the Human Genome Epidemiology Network for reporting gene-disease associations. Results the search has retrieved 800 results, among which only 7 studies have met the eligibility criteria for inclusion in the analysis. The latter are case-control studies of genetic association and an exploratory analysis and two polymorphisms have been detected as the most recurring: the rs3781719 (T > C) of the CALC A gene encoding CGRP and the rs7590387 of the gene encoding the receptor activity-modifying protein (RAMP) 1 (C > G). Only one study assessing the methylation pattern with regard to CGRP pathway has been found from the search. No genetic association studies investigating the possible effect of genetic variants affecting CGRP signaling on the responsiveness to the most recent pharmacological approaches, i.e. anti-CGRP(R) mAbs, gepants and ditans, have been published. According to the Human Genome Epidemiology (HuGE) systematic reviews and meta-analyses risk-of-bias score for genetic association studies, the heterogeneity between and across studies and the small sample size do not allow to draw conclusions and prompt future studies. Conclusions adequately powered, good quality genetic association studies are needed to understand the impact of genetic variants affecting the pathway of CGRP on migraine susceptibility and clinical manifestation and to predict the response to therapy in terms of efficacy and safety.
- Published
- 2021
- Full Text
- View/download PDF
39. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol
- Author
-
D. Scuteri, F. Guida, S. Boccella, L. Luongo, S. Maione, P. Tonin, P. Nicotera, G. Bagetta, and M.T. Corasaniti
- Subjects
Nabiximols ,Sativex® ,Cannabinoids ,Severe dementia ,Pain ,Agitation ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Up to 80 % nursing home residents with dementia experiences chronic pain. Contextually, 97 % presents fluctuant neuropsychiatric symptoms (NPS). Among the most challenging is agitation, connected with undertreated pain and managed through neuroleptics doubling death risk. Evidence is accumulating in favor of the involvement of the endocannabinoid system in nociception and NPS. This double-blind, placebo-controlled, randomized trial (NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia [NACTOPAISD]) aims at investigating efficacy and safety of oral spray nabiximols, containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex®), for pain and agitation treatment in severe dementia patients (Mini-Mental State Examination ≤ 12) over 65. The coprimary endpoints are efficacy on pain and agitation, assessed through the recently validated Italian Mobilization–Observation–Behavior–Intensity–Dementia and the Cohen-Mansfield Agitation Inventory. The secondary endpoint is the evaluation of efficacy duration after wash-out and the assessment of quality of life through the DEMQOL. Any adverse events will be reported. The results undergo statistical analysis plan. NACTOPAISD might provide rationale for a translational safer pain and agitation treatment in severe dementia. It is approved by Calabria Region Ethics Committee and follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and the Consolidated Standards of Reporting Trials (CONSORT) statements.
- Published
- 2022
- Full Text
- View/download PDF
40. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Author
-
Maria Tiziana Corasaniti, Giacinto Bagetta, Pierluigi Nicotera, Assunta Tarsitano, Paolo Tonin, Giorgio Sandrini, Gary W. Lawrence, and Damiana Scuteri
- Subjects
onabotulinumtoxin A ,chronic migraine ,safety ,treatment-related adverse events (TRAEs) ,PRISMA 2020 ,Medicine - Abstract
Some 14% of global prevalence, based on high-income country populations, suffers from migraine. Chronic migraine is very disabling, being characterized by at least 15 headache days per month of which at least 8 days present the features of migraine. Onabotulinumtoxin A, targeting the machinery for exocytosis of neurotransmitters and neuropeptides, has been approved for use in chronic migraine since 2010. This systematic review and meta-analysis appraises the safety of onabotulinumtoxin A treatment for chronic migraine and the occurrence of treatment-related adverse events (TRAEs) in randomized, clinical studies in comparison with placebo or other comparators and preventative treatments according to the most updated Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 recommendations. The search retrieved 888 total records. Nine studies are included and seven were eligible for meta-analysis. The present study demonstrates that toxin produces more TRAEs than placebo, but less than oral topiramate, supporting the safety of onabotulinumtoxin A, and highlights the heterogeneity of the studies present in the literature (I2 = 96%; p < 0.00001). This points to the need for further, adequately powered, randomized clinical trials assessing the safety of onabotulinumtoxin A in combination with the newest treatment options.
- Published
- 2023
- Full Text
- View/download PDF
41. Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis
- Author
-
Maria Tiziana Corasaniti, Giacinto Bagetta, Luigi Antonio Morrone, Paolo Tonin, Kengo Hamamura, Takafumi Hayashi, Francesca Guida, Sabatino Maione, and Damiana Scuteri
- Subjects
cancer pain ,oncologic pain ,tumor pain ,essential oils ,aromatherapy ,integrative medicine ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Over 80% of patients affected by cancer develops cancer-related pain, one of the most feared consequences because of its intractable nature, particularly in the terminal stage of the disease. Recent evidence-based recommendations on integrative medicine for the management of cancer pain underline the role of natural products. The present systematic review and meta-analysis aims at appraising for the first time the efficacy of aromatherapy in cancer pain in clinical studies with different design according to the most updated Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 recommendations. The search retrieves 1002 total records. Twelve studies are included and six are eligible for meta-analysis. The present study demonstrates significant efficacy of the use of essential oils in the reduction of the intensity of pain associated with cancer (p < 0.00001), highlighting the need for earlier, more homogeneous, and appropriately designed clinical trials. Good certainty body of evidence is needed for effective and safe management of cancer-related pain using essential oils by establishment of a step-by-step preclinical-to-clinical pathway to provide a rational basis for clinical use in integrative oncology. PROSPERO registration: CRD42023393182.
- Published
- 2023
- Full Text
- View/download PDF
42. Phone calls for improving blood pressure control among hypertensive patients attending private medical practitioners in India: Findings from Mumbai hypertension project
- Author
-
Mandar Kannure, Asha Hegde, Anupam Khungar‐Pathni, Bhawna Sharma, Angelo Scuteri, Dinesh Neupane, Ravdeep Kaur Gandhi, Haresh Patel, Sapna Surendran, Vaishnavi Jondhale, Suman Gupta, Ajit Phalake, Vrushal Walkar, Roshini George, Helen Mcguire, Neeraj Jain, and Shibu Vijayan
- Subjects
blood pressure control ,follow‐up visit ,mHealth ,Mumbai Hypertension Project ,phone calls ,India ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Despite the availability of effective medication, blood pressure control rates are low, particularly in low‐ and middle‐income countries. Adherence to medication and follow‐up visits are important factors in blood pressure control. This study assessed the effectiveness of reminder telephone calls on follow‐up visits and blood pressure control among hypertensive patients as part of the Mumbai Hypertension Project. This project was initiated by PATH with the support from Resolve to Save Lives from January 2019 to February 2020. The study included hypertensive patients attending 164 private practices in Mumbai, India; practitioners screened all adults visiting their clinic during the project period. Among 13 184 hypertensive patients registered, the mean age was 53 years (SD = 12.38) and 52% were female. Among the 11 544 patients that provided phone numbers and gave consent for follow‐up calls, 9528 responded to phone calls at least once and 5250 patients followed up at least once. Of the 5250 patients, 82% visited the clinic for follow‐up visit within one month after receiving the phone call. The blood pressure control rate among those who answered phone calls and who did not answer phone calls increased from 23.6% to 48.8% (P
- Published
- 2021
- Full Text
- View/download PDF
43. CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic review
- Author
-
Gabriele Gallo Afflitto, Francesco Aiello, Damiana Scuteri, Giacinto Bagetta, and Carlo Nucci
- Subjects
Cannabinoid ,Endocannabinoid system ,Neuroprotection ,Glaucoma ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: The endocannabinoid system (ECS) is a complex biological regulatory system. Its expression and functionality have been widely investigated in ocular tissues. Recent data have reported its modulation to be valid in determining an ocular hypotensive and a neuroprotective effect in preclinical animal models of glaucoma. Aim: This study aimed to explore the available literature on cannabinoid receptor 1 (CB1R), cannabinoid receptor 2 (CB2R), and transient receptor potential vanilloid 1 (TRPV1) expression in the trabecular meshwork (TM), ciliary body (CB), and retina as well as their ocular hypotensive and neuroprotective effects in preclinical, in vivo, animal glaucoma models. Materials and methods: The study adhered to both PRISMA and SYRCLE guidelines. Sixty-nine full-length articles were included in the final analysis. Results: Preclinical studies indicated a widespread distribution of CB1R, CB2R, and TRPV1 in the TM, CB, and retina, although receptor-, age-, and species-dependent differences were observed. CB1R and CB2R modulation have been shown to exert ocular hypotensive effects in preclinical models via the regulation of inflow and outflow pathways. Retinal cell neuroprotection has been achieved in several experimental models, mediated by agonists and antagonists of CB1R, CB2R, and TRPV1. Discussion: Despite the growing body of preclinical data regarding the expression and modulation of ECS in ocular tissues, the mechanisms responsible for the hypotensive and neuroprotective efficacy exerted by this system remain largely elusive. Research on this topic is advocated to further substantiate the hypothesis that the ECS is a new potential therapeutic target in the context of glaucoma.
- Published
- 2022
- Full Text
- View/download PDF
44. Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing
- Author
-
D. Scuteri, M. Contrada, T. Loria, D. Sturino, A. Cerasa, P. Tonin, G. Sandrini, S. Tamburin, A.C. Bruni, P. Nicotera, M.T. Corasaniti, and G. Bagetta
- Subjects
MOBID-2 ,Italian translation and validation ,Psychometric properties ,Validity ,Reliability ,I-MOBID2 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The 97% of dementia patients develops fluctuant neuropsychiatric symptoms often related to under-diagnosed and unrelieved pain. Up to 80% severe demented nursing home residents experiences chronic pain due to age-related comorbidities. Patients lacking self-report skills risk not to be appropriately treated for pain. Mobilization–Observation–Behavior–Intensity–Dementia (MOBID2) is the sole pain scale to consider the frequent co-occurrence of musculoskeletal and visceral pain and to unravel concealed pain through active guided movements. Accordingly, the Italian real-world setting can benefit from its translation and validation. This clinical study provides a translated, adapted and validated version of the MOBID2, the Italian I-MOBID2. The translation, adaptation and validation of the scale for non-verbal, severe demented patients was conducted according to current guidelines in a cohort of 11 patients over 65 with mini-mental state examination ≤ 12. The I-MOBID2 proves: good face and scale content validity index (0.89); reliable internal consistency (Cronbach’s α = 0.751); good to excellent inter-rater (Intraclass correlation coefficient, and test-retest (ICC = 0.902) reliability. The construct validity is high (Rho = 0.748 p
- Published
- 2022
- Full Text
- View/download PDF
45. Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review
- Author
-
Giuseppe Giannaccare, Andrea Lucisano, Marco Pellegrini, Gianfranco Scuteri, Alessandra Mancini, Cristina Malaventura, Massimo Busin, and Vincenzo Scorcia
- Subjects
Congenital corneal anesthesia ,Neurotrophic keratopathy ,Serum eye drops ,Blood-derived eye drops ,Ophthalmology ,RE1-994 - Abstract
Purpose: To report the feasibility and the successful outcomes of a pediatric neurotrophic keratopathy (NK) owing to congenital corneal anesthesia (CCA) treated with allogeneic serum eye drops obtained from the mother as the only therapy. Observations: A 18-month-old girl with generalized pain insensitivity presented with a large epithelial defect in the right eye (RE) and superficial punctate keratopathy (SPK) in the left eye (LE). Corneal sensitivity was completely absent in both eyes (BE). Peripheral serum eye drops obtained from the mother was prescribed and administered every 2 hours in BE. Two weeks after the beginning of treatment, compete healing of the epithelial defect in the RE was obtained, while the severity of the SPK in the LE markedly improved; in parallel, conjunctival hyperemia disappeared in BE. The treatment was continued over the course of 3 months with good tolerability and neither signs of recurrence of the epithelial defect nor other complications were noted. Conclusions and Importance: Allogeneic serum eye drops obtained from the mother are effective in treating pediatric NK owing to CCA. This treatment may represent a readily available and inexpensive option when topical nerve growth factor is unavailable or corneal neurotization is not feasible.
- Published
- 2022
- Full Text
- View/download PDF
46. Thermal and Visual Tracking of Photovoltaic Plants for Autonomous UAV inspection.
- Author
-
Luca Morando, Carmine Tommaso Recchiuto, Jacopo Calla, Paolo Scuteri, and Antonio Sgorbissa
- Published
- 2022
47. Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia
- Author
-
Yvelise Ferro, Elisa Mazza, Elvira Angotti, Roberta Pujia, Angela Mirarchi, Maria Antonietta Salvati, Rosa Terracciano, Rocco Savino, Stefano Romeo, Antonio Scuteri, Rosario Mare, Francesco Saverio Costanzo, Arturo Pujia, and Tiziana Montalcini
- Subjects
Functional food ,Tomato sauce ,Sterols ,Carotenoids ,Lipids ,Cholesterol ,Medicine - Abstract
Abstract Background Most studies focused on the benefits of lycopene on serum lipids but no studies have been specifically designed to assess the role of a tomato sauce from vine-ripened tomatoes on patients affected by polygenic hypercholesterolemia. The aim of this study was to compare the lipid-lowering effect of a novel functional tomato sauce with a well-known functional food with a lipid-lowering effect, i.e. a sterol-enriched yogurt. Methods In this cross-over study, we evaluated a population of 108 ambulatory patients affected by polygenic hypercholesterolemia of both gender, who were allocated to a tomato sauce (namely OsteoCol) 150 ml/day or a sterol-enriched yogurt (containing sterols 1.6 g/die) treatment, for 6 weeks. Carotenoids content was 3.5 mg per gram of product. We measured serum lipids and creatinine and transaminases at basal and follow-up visit. Results A total of 91 subjects completed the protocol. A significant difference in LDL-cholesterol change was found between participants taking yogurt, tomato sauce (high adherence) and tomato sauce (low adherence) (− 16; − 12; + 8 mg/dl respectively; p
- Published
- 2021
- Full Text
- View/download PDF
48. Pancytopenia Secondary to Vitamin B12 Deficiency in Older Subjects
- Author
-
Giulia Costanzo, Giada Sambugaro, Giulia Mandis, Sofia Vassallo, and Angelo Scuteri
- Subjects
aging ,vitamin B12 ,megaloblastic anemia ,pancytopenia ,Medicine - Abstract
Background: Vitamin B12 (cobalamin CBL) is a water-soluble vitamin required to form hematopoietic cells (red blood cells, white blood cells, and platelets). It is involved in the process of synthesizing DNA and myelin sheath. Deficiencies of vitamin B12 and/or folate can cause megaloblastic anemia (macrocytic anemia with other features due to impaired cell division). Pancytopenia is a less frequent exordium of severe vitamin B12 deficiency. Vitamin B12 deficiency can also cause neuropsychiatric findings. In addition to correcting the deficiency, an essential aspect of management is determining the underlying cause because the need for additional testing, the duration of therapy, and the route of administration may differ depending on the underlying cause. Methods: Here, we present a series of four patients hospitalized for megaloblastic anemia (MA) in pancytopenia. All patients diagnosed with MA were studied for a clinic-hematological and etiological profile. Results: All the patients presented with pancytopenia and megaloblastic anemia. Vitamin B12 deficiency was documented in 100% of cases. There was no correlation between the severity of anemia and deficiency of the vitamin. Overt clinical neuropathy was present in none of the cases of MA, while subclinical neuropathy was seen in one case. The etiology of vitamin B12 deficiency was pernicious anemia in two cases and low food intake in the remaining cases. Conclusion: This case study emphasizes the role of vitamin B12 deficiency as a leading cause of pancytopenia among adults.
- Published
- 2023
- Full Text
- View/download PDF
49. Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity
- Author
-
Eleonora Pozzi, Elisa Ballarini, Virginia Rodriguez-Menendez, Annalisa Canta, Alessia Chiorazzi, Laura Monza, Mario Bossi, Paola Alberti, Alessio Malacrida, Cristina Meregalli, Arianna Scuteri, Guido Cavaletti, and Valentina Alda Carozzi
- Subjects
peripheral neurotoxicity ,peripheral neuropathy ,chemotherapy ,paclitaxel ,cisplatin ,satellite glial cells ,Chemical technology ,TP1-1185 - Abstract
Chemotherapy-induced peripheral neurotoxicity is one of the most common dose-limiting toxicities of several widely used anticancer drugs such as platinum derivatives (cisplatin) and taxanes (paclitaxel). Several molecular mechanisms related to the onset of neurotoxicity have already been proposed, most of them having the sensory neurons of the dorsal root ganglia (DRG) and the peripheral nerve fibers as principal targets. In this study we explore chemotherapy-induced peripheral neurotoxicity beyond the neuronocentric view, investigating the changes induced by paclitaxel (PTX) and cisplatin (CDDP) on satellite glial cells (SGC) in the DRG and their crosstalk. Rats were chronically treated with PTX (10 mg/Kg, 1qwx4) or CDDP (2 mg/Kg 2qwx4) or respective vehicles. Morpho-functional analyses were performed to verify the features of drug-induced peripheral neurotoxicity. Qualitative and quantitative immunohistochemistry, 3D immunofluorescence, immunoblotting, and transmission electron microscopy analyses were also performed to detect alterations in SGCs and their interconnections. We demonstrated that PTX, but not CDDP, produces a strong activation of SGCs in the DRG, by altering their interconnections and their physical contact with sensory neurons. SGCs may act as principal actors in PTX-induced peripheral neurotoxicity, paving the way for the identification of new druggable targets for the treatment and prevention of chemotherapy-induced peripheral neurotoxicity.
- Published
- 2023
- Full Text
- View/download PDF
50. Automated digital analysis of intraoperative keratoscopy and its correlation with postoperative astigmatism after big-bubble deep anterior lamellar keratoplasty
- Author
-
Giannaccare, Giuseppe, Lucisano, Andrea, Pellegrini, Marco, Bernabei, Federico, Scuteri, Gianfranco, and Scorcia, Vincenzo
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.